-
Recornea received a grant from the Autonomous Region of Friuli Venezia Giulia
This grant will support key activities aimed at the full validation of the GROSSO® Reshaper, including clinical protocol refinement, production optimization, regulatory compliance, and the execution of multi-center clinical trials.
-
GROSSO® Reshaper FIH Trial: New Clinical Site Approved in Italy
The GROSSO® Reshaper First-In-Human (FIH) trial is expanding its reach in Italy following the approval from the "Comitato Etico Territoriale Lazio Area 3" and the formal authorization from the Italian Ministry of Health.
-
GROSSO® Reshaper FIH Trial: Enrollment Update and Clinical Progress
The GROSSO® Reshaper First-In-Human (FIH) study continues to advance its clinical evaluation, with four patients already successfully recruited and treated at the IMO Grupo Miranza in Barcelona, Spain.
-
GROSSO® Reshaper FIH Trial: Three New Patients Treated in Barcelona
The GROSSO® Reshaper First-In-Human (FIH) trial has progressed with the treatment of three new patient sat the Institute of Ocular Microsurgery (IMO) in Barcelona, Spain.
Preventing your blindness through innovation - 000
It's not about ideas.
It's about making ideas happen.
Innovative Eye Care Solutions
Recornea technologies prevent blindness through proprietary technology that creates innovative minimally-invasive products for ophthalmic applications. The technology couples minimally invasive surgery with biocompatible and bio-enhanced devices to treat diseases of the eye.
Our technology:
- Nitinol A super elastic, shape-memory alloy.
- Biocompatible devices designed for natural integration/engineered for safety.
- Minimally invasive procedures Faster healing, less pain.
Pioneering the Future of Ophthalmology
RECORNEA pioneers advanced medical solutions for diseases of the eye. Our flagship GROSSO® Reshaper is the world's first-ever nitinol intracorneal implant designed to treat keratoconus, a condition that causes progressive thinning and bulging of the cornea resulting in poor quality of vision. By leveraging the unique properties of shape-memory and super-elastic materials, we are developing a pipeline of innovative minimally-invasive devices to address a wide range of ocular conditions, including glaucoma and keratoconus.
Supported by Fundings & Patents
Recornea raised around €4.4 M in non-dilutive and €1.4 M in dilutive funding for the core platform proprietary technology. Recornea will spin out multiple innovative products such as for glaucoma related ailments and others in the coming years.
Updates from Recornea world
Latest News
